Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavrilimumab in Severe COVID-19 Pneumonia
NCT04447469Phase 3Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of mavrilimumab in coronavirus disease 2019 (COVID-19), sponsored by Kiniksa Pharmaceuticals. Started Jul 2020; status: completed.
02
Drugs
mavrilimumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04447469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447469.